Format

Send to

Choose Destination
Otolaryngol Head Neck Surg. 2005 Aug;133(2):251-9.

Intratympanic steroid injection for treatment of idiopathic sudden hearing loss.

Author information

1
House Ear Institute, House Ear Clinic, Los Angeles, California 90057, USA. wslattery@hei.org

Abstract

OBJECTIVE:

To conduct a clinical trial of intratympanic steroid injection for idiopathic sudden sensorineural hearing loss in subjects who failed oral steroid therapy.

STUDY DESIGN AND SETTING:

Open-label methylprednisolone injection clinical trial in a tertiary neurotologic referral center. Twenty subjects (14 males; 6 females) received 4 injections within a 2-week period (4 days apart). Hearing, dizziness, and tinnitus were evaluated before and after treatment.

RESULTS:

There were no serious unexpected adverse events and 2 types of expected adverse events (tympanic membrane perforation, nausea after injection). No increases in dizziness or tinnitus lasting longer than 24 hours were observed after injections. One of 20 (5%) improved to near-normal hearing. In addition, there was statistically significant improvement in 4-frequency pure-tone average and speech discrimination score at 1 month after treatment.

CONCLUSION:

Four intratympanic injections of methylprednisolone improved pure-tone average or speech discrimination scores for a subset of sudden hearing loss subjects that failed to benefit from oral steroids.

SIGNIFICANCE:

A clinical trial of intratympanic injections for idiopathic sudden hearing loss was successfully completed and promising results were found.

PMID:
16087024
DOI:
10.1016/j.otohns.2005.05.015
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center